Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.
Saved in:
| Title: | Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. |
|---|---|
| Authors: | Schwab N; (Muenster, Germany)., Schneider-Hohendorf T; (Muenster, Germany)., Pignolet B; (Toulouse, France)., Brassat D; (Toulouse, France)., Wiendl H; (Muenster, Germany). |
| Source: | Neurology [Neurology] 2020 Sep 15; Vol. 95 (11), pp. 505. |
| Publication Type: | Journal Article; Comment |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
